OIOsamu Inaba

Osamu Inaba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Osamu Inaba has a total of 302 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Predictors of Favorable Neurological Outcomes Following Atrioesophageal Fistula After Radiofrequency Catheter Ablation for Atrial Fibrillation: A Subanalysis of the POTTER-AF Study

    by Kohei Ukita, Sorin Stefan Popescu, Vanessa Schmidt, Helmut Pürerfellner, Philipp Sommer, Christian Sohns, Christian Veltmann, Daniel Steven, K.R. Julian Chun, Philippe Maury, et al.

  • Role of Interatrial Septal Adipose Tissue Volume and Attenuation in Predicting Atrial Tachyarrhythmias Recurrence Following Catheter Ablation

    by Shinichi Tachibana, Osamu Inaba, Yukihiro Inamura, Takamitsu Takagi, Kentaro Nakata, Yuhei Isonaga, Hiroaki Ohya, Yutaka Matsumura, Shinsuke Miyazaki, Tetsuo Sasano

    Background: Left atrial epicardial adipose tissue (LA‐EAT) is associated with atrial tachyarrhythmia (AF/AT) recurrence following atrial fibrillation (AF) ablation, of which we recently reported interatrial septal adipose tissue (IAS‐AT) has a higher predictive value. This study evaluated the predictive value of IAS‐AT volume/attenuation for AF/AT recurrence and compared it with that of other LA–EAT segments. Methods: Preoperative multidetector computed tomography (CT) was performed on 350 consecutive patients undergoing initial AF ablation. LA‐EAT was defined as tissue with CT attenuation between −190 and −30 Hounsfield units (HU), and IAS‐AT was specifically measured in the atrial septum. Results: AF/AT recurrence occurred in 71 patients (20.3%) during a mean follow‐up of 408 ± 142 days. The mean IAS‐AT volume was 1.8 ± 1.5 mL, and attenuation was −69.3 ± 8.9 HU. IAS‐AT volume (≥ 1.7 mL; hazard ratio [HR] 2.12, 95% confidence interval [CI] 1.26–3.56, p = 0.004) and attenuation (≤−66.7 HU; HR 2.31, 95% CI 1.25–4.26, p = 0.007) were independent predictors of AF/AT recurrence. Receiver operating characteristic analyses revealed that the predictive value of IAS‐AT attenuation was comparable to that of LA‐EAT attenuation other than IAS‐AT (area under the curve (AUC), 0.611 vs. 0.602; p = 0.815). However, IAS‐AT volume was superior to LA‐EAT volume other than IAS‐AT in predicting recurrent AF/AT (AUC, 0.67 vs. 0.58; p = 0.001). Conclusion: IAS‐AT volume and attenuation are significant predictors of AF/AT recurrence, with IAS‐AT volume providing an enhanced predictive value compared to other LA‐EAT segment volumes. IAS‐AT may be an indicator of AF/AT recurrence after AF ablation.

  • Two Different Cryoballoon Systems for Treatment of Paroxysmal Atrial Fibrillation: Results From the CONTRAST-CRYO Trial

    by Shinsuke Miyazaki, Junichi Nitta, Kohki Nakamura, Atsushi Kobori, Osamu Inaba, Masato Murakami, Yasuteru Yamauchi, Yukio Sekiguchi, Takehito Sasaki, Yasuhiro Sasaki, et al.


  • One‐Year Clinical Outcomes of Novel Dual‐Sized Cryoballoon Ablation for Atrial Fibrillation

    by Yosuke Hayashi, Shinsuke Miyazaki, Junichi Nitta, Takeshi Sasaki, Yasuteru Yamauchi, Osamu Inaba, Yukio Sekiguchi, Shu Yamashita, Yuichiro Sagawa, Yukihiro Inamura, et al.

    Background: Clinical outcomes after atrial fibrillation (AF) ablation using the novel dual‐sized cryoballoon (DS‐CB) are limited. This study aimed to analyze real‐world data on the DS‐CB. Methods: This multicenter observational study included consecutive AF patients who underwent pulmonary vein (PV) isolation (PVI) using a DS‐CB catheter (28‐mm/31‐mm). Results: In 407 patients (68 ± 11 years, 279 men, 251 paroxysmal AF[PAF]), 1528 (95.9%) out of 1594 targeted PVs were successfully isolated with DS‐CBs. The total application number and application time were 5 [4‐6] and 812 ± 207 s, respectively. Cryoballoon‐related phrenic nerve injury (PNI) occurred in 23 (5.6%) patients, with 4.7% in the right superior PV (RSPV) and 1.0% in the right inferior PV. All but one patient recovered within 12 months. Additional ablation beyond CB‐PVI was performed in 251 (62%) patients. The 1‐year arrhythmia freedom was 91.7% (93.3% for PAF and 89.5% for non‐PAF, p = 0.08), with antiarrhythmic drug use in 23 (9.2%) and 32 (20.6%) PAF and non‐PAF patients, respectively. Forty‐three patients experienced early recurrence of AF (ERAF) within 2 months of follow‐up. In a multivariate Cox regression analysis, including baseline and procedural parameters, a higher nadir balloon temperature in the RSPV (hazard ratio[HR] = 1.076, 95% confidence interval[CI] = 1.024–1.130, p < 0.01) and all 4 PVI with 31‐mm balloons (HR = 3.085, 95% CI = 1.701–5.595, p < 0.01) were significantly associated with arrhythmia recurrence. In the multivariate analysis including all parameters, ERAF (HR = 5.066, 95% CI = 2.928–8.767, p < 0.01) was the strongest predictor of arrhythmia recurrence. Conclusions: The 1‐year arrhythmia freedom post‐DS‐CB ablation was 91.7% in real‐world clinical practice; however, right PNI remained a common complication, even with the balloon size adjustability.


  • Chasing Conduction Gaps Across the Roof Line: Nearby and Overlap Better Than Appendage Pacing

    by Takamitsu Takagi, Osamu Inaba, Yukihiro Inamura, Akira Sato, Yuhei Isonaga, Shinichi Tachibana, Hiroaki Ohya, Allan Plant, Romain Tixier, Josselin Duchateau, et al.

    BACKGROUND: Blocking a line depends not only on the ablation but also on the validation technique. We sought to compare the performance of different pacing modes for roof line validation. METHODS: Fifty consecutive patients underwent atrial fibrillation ablation, which included a roof line and a floor line. Floor line block was mandatory for clear evaluation of the roof line, the block of which was demonstrated by a box isolation of the dome. Before floor line creation, first-pass roof line evaluation was based on high-density mapping while pacing from either: (1) the left appendage; (2) just above the line; or (3) with an overlapping multispline catheter. RESULTS: Roof line mapping was feasible in all patients (100%) during left appendage and nearby pacing, and in 45 (90%) patients during overlap pacing. Left appendage pacing sensitivity for true gaps was significantly lower than nearby (48% versus 97%; P P P =0.001) and overlap (50% versus 89%; P =0.004) pacing. Double potentials during left appendage pacing were shorter than during nearby pacing (63±20 ms versus 103±22 ms; P <0.001). In 1 patient, a slow conduction gap was unmasked only after floor line block. Final box isolation of the dome was achieved in 47 (94%) patients. CONCLUSIONS: The longer the activation delay from one side of a line to the other, the greater the chance to unmask a slow conduction gap across the line. Nearby pacing thus better identifies roof line gaps than left appendage pacing. Overlap pacing offers a simple and fast alternative with similar performance.


  • Impact of Increased Cryoballoon Size on the Left Atrium, Superior Vena Cava, and Phrenic Nerve

    by Yukihiro Inamura, Osamu Inaba, Takamitsu Takagi, Yuhei Isonaga, Shinichi Tachibana, Hiroaki Ohya, Akira Sato, Shinsuke Miyazaki, Junichi Nitta, Tetsuo Sasano

    Background: POLARx FIT is a size‐adjustable cryoballoon, but its effect on isolation area and phrenic nerve injury (PNI) is not fully understood. This study aimed to compare the effects of 28 and 31 mm cryoballoon on the left atrium (LA), superior vena cava (SVC), and PNI incidence.Methods and Results: Thirty‐one cases of paroxysmal atrial fibrillation treated with POLARx FIT were analyzed. SVC voltage mapping and septal sleeve length measurements were performed before pulmonary vein (PV) isolation. A 28 mm balloon was used to isolate four PVs, followed by SVC and LA mapping. Additional ablation of the superior PVs was performed with a 31 mm balloon, and remapping was conducted. The isolation area of the LA, SVC sleeve length, and PNI incidence were compared before treatment, after the 28 mm treatment, and after the 31 mm treatment. The residual LA posterior wall area was significantly smaller with the 31 mm balloon compared to the 28 mm balloon (p < 0.01), with a significant increase in isolation area on the right side of the PVs after 31 mm treatment (p = 0.03). SVC sleeve length progressively shortened with increasing balloon size, showing a significant reduction between pretreatment and after the 31 mm treatment (p = 0.02). No consistent association was observed between balloon size and PNI.Conclusions: The larger cryoballoon expanded the LA posterior wall isolation area and had a greater effect on the SVC. Balloon size and PNI have shown inconsistent results.


  • Open Access

    Real‐World Impact of Steerable Sheaths for Paroxysmal Atrial Fibrillation Catheter Ablation: The INSIGHT Study

    by Yasuo Okumura, Tsunesuke Kono, Akira Mizukami, Osamu Inaba, Yuji Wakamatsu, Daisuke Yamagishi, Satoshi Nakamura, Takumi Arashiro, Akira Sato, Yi Wang, et al.

    Introduction: In atrial fibrillation (AF) ablation procedures, the CARTO VIZIGO Bidirectional Guiding Sheath has previously shown promising results in reducing fluoroscopy times without compromising clinical effectiveness or safety compared with non‐steerable sheaths.Methods: This non‐randomized, multicenter, retrospective cohort study (INSIGHT) aimed to determine the real‐world impact of the VIZIGO sheath on procedural efficiency, clinical effectiveness, and safety in paroxysmal AF (PAF) catheter ablation. Consecutive adults who underwent de novo radiofrequency (RF) ablation for PAF with a non‐VIZIGO sheath (January 2019–July 2021) or VIZIGO sheath (January 2020–July 2021) were included. Procedural characteristics, primary adverse events (PAEs), and 12‐month effectiveness (freedom from repeat ablation or recurrent atrial arrhythmia) were evaluated.Results: Of 199 patients included (mean age, 69.7 years; 59.3% male), 97 had ablation with a VIZIGO sheath and 102 with a non‐VIZIGO sheath. Significantly shorter mean times were achieved in the VIZIGO vs. non‐VIZIGO group for time to left PVI (18.1 ± 7.5 vs. 19.9 ± 5.6 min, p = 0.046), right PVI (16.5 ± 6.1 vs. 23.1 ± 9.9 min, p < 0.001), total PVI (34.6 ± 9.7 vs. 42.9 ± 11.4 min, p = 0.002), and fluoroscopy time (7.3 ± 10.4 vs. 18.3 ± 13.3 min, p < 0.001). Mean fluoroscopy dose was significantly lower (45.9 ± 112.0 vs. 139.5 ± 251.5 mGy, p < 0.001) with VIZIGO vs. non‐VIZIGO sheaths. Catheter stability was comparable between groups. PAE rates were similar in the VIZIGO (3.1%) and non‐VIZIGO (4.9%) groups. Freedom from repeat ablation and recurrent atrial arrhythmia at 12 months were also similar in the two groups.Conclusion: These real‐world data demonstrate that use of the VIZIGO sheath in PAF ablation procedures allows for significantly lower fluoroscopy time and dose with significantly shorter PVI isolation time, without compromising acute and long‐term effectiveness or safety.


  • Temperature-controlled bipolar radiofrequency ablation: An ex vivo study for optimizing efficacy and safety parameters

    by Osamu Inaba, Yukihiro Inamura, Takamitsu Takagi, Shin Meguro, Kentaro Nakata, Toshiki Michishita, Yuhei Isonaga, Shinichi Tachibana, Hiroaki Ohya, Akira Sato, et al.


  • Open Access

    Real‐world clinical practice of current periprocedural anticoagulation management in catheter ablation of atrial fibrillation: Data from a large prospective ablation registry

    by Yuta Taomoto, Shinsuke Miyazaki, Yasutoshi Nagata, Junichi Nitta, Osamu Inaba, Yasuhiro Shirai, Yasuaki Tanaka, Yukio Sekiguchi, Yukihiro Inamura, Yuichiro Sagawa, et al.

    Background: The guidelines recommend anticoagulation management with uninterrupted warfarin or direct thrombin inhibitors (DTIs) during the atrial fibrillation (AF) ablation periprocedural period. Objectives: To clarify the Japanese real‐world latest periprocedural anticoagulation management during AF ablation. Methods: This multicenter observational study included 6232 consecutive AF patients (68.7 ± 10.9 years, 4346 men) who underwent periprocedural anticoagulation therapy using direct oral anticoagulants (DOACs) between January 2022 and August 2023. Results: The mean CHADS 2 and CHA 2 DS 2 VASc scores were 1.2 ± 1.1 and 2.3 ± 1.5. Bleeding and thromboembolic events occurred in 79 (1.3%) and eight (0.12%) patients. During the periprocedural period, factor Xa inhibitors (FXaIs) were used in 3063 patients (rivaroxaban in 624, apixaban in 1093, and edoxaban in 1345) and DTIs in 3170 including 2583 in whom DTIs were switched from FXaIs. Both the bleeding (0.85% vs. 1.69%, p = .003) and thromboembolic event rates (0.03% vs. 0.23%, p = .036) were significantly lower in the DTI‐ than FXaI‐group. A multivariate analysis showed periprocedural FXaI use was significantly associated with both bleeding events (odds ratio [OR] = 1.92, 95% confidence interval [CI] = 1.20–3.08, p = .006) and cardiac tamponade (OR = 2.74, 95% CI = 1.27–5.9, p = .01). The interval between the last DOAC administration and the procedure was significantly shorter in the DTI‐ than FXaI‐group (4.2 ± 4.9 vs. 19.3 ± 10.7 h, p < .01). In the FXaI‐group, the bleeding rate tended to be lower in the minimally interrupted ( n = 2105) than uninterrupted group ( n = 821) (1.47% vs. 2.56%, p = .06). Two patients in the uninterrupted FXaI‐group required surgical management for cardiac tamponade. Conclusions: Our multicenter real‐world data demonstrated that anticoagulation with DTIs was a reasonable periprocedural anticoagulation regimen to reduce periprocedural complications.


  • Impact of the Individual Operator Experience and Learning Curve of a Novel Size Adjustable Cryoballoon

    by Yosuke Hayashi, Shinsuke Miyazaki, Junichi Nitta, Osamu Inaba, Yuichiro Sagawa, Shinsuke Iwai, Yukio Sekiguchi, Yukihiro Inamura, Yasuteru Yamauchi, Kentaro Goto, et al.

    Background: Cryoballoon ablation is less operator‐dependent than radiofrequency ablation. Recently, size‐adjustable cryoballoons (SA‐CBs) have become available. We sought to analyze the individual baseline operator experience's impact on procedural results.Methods: This multicenter observational study included atrial fibrillation (AF) patients who underwent pulmonary vein (PV) isolation using SA‐CBs capable of 28‐mm or 31‐mm balloon sizes. Experienced (E‐group) or less experienced (LE‐group) operators were defined as experiencing > 100 or ≤ 100 cryoballoon procedures, respectively.Results: Among 510 patients (67 ± 11 years, 355 men, 325 paroxysmal AF [PAF]) who underwent an SA‐CB ablation, 240 and 270 were in the E‐group and LE‐group, respectively. All cryoballoon parameters were similar between the groups, except for a significantly higher 31‐mm balloon isolation rate in the E‐group than LE‐group, especially for right superior PVs. Cryoballoon‐related phrenic nerve injury occurred in 34 (6.7%) patients and tended to be higher in the LE‐group than E‐group (8.1% vs. 5.0%, p = 0.16). The AF freedom was comparable between the groups for both PAF and non‐PAF patients. A total of 36(7.1%) patients underwent re‐do procedures at 5.2 ± 2.6 months post‐index procedure. The PV reconnection rate was significantly higher in the LE‐group than E‐group (27.1% vs. 8.9%, p < 0.01), and this trend was more pronounced for right PVs than left PVs.Conclusions: In AF ablation using SA‐CBs, the overall procedural efficacy and safety were comparable between the E‐group and LE‐group. However, 100 CB procedures seemed to still be in the middle of a learning curve for selecting the balloon size and balloon position, especially for right PVs.